BTIG raised the firm’s price target on Boston Scientific (BSX) to $132 from $127 and keeps a Buy rating on the shares. The firm notes the company’s biennial investor day Tuesday in NYC, during which Boston Scientific set 2026-2028 financial targets including an organic revenue CAGR of over 10%, operating margin expansion of 50 bps per year, double-digit adjusted EPS growth, and 70%-80% free cash flow conversion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $128 from $123 at Baird
- Boston Scientific price target raised to $132 from $131 at Canaccord
- Boston Scientific’s Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Promising Growth Trajectory: A Buy Rating Backed by Strong Financial Targets and Key Franchises
- Boston Scientific’s Promising Growth Trajectory: Buy Rating Supported by Innovative Products and Strategic Expansion